PhD students Dimitris Kotsos and Amica Ko have both won ASH Abstract Achievement Awards.
Dimitris Kotsos
What is the preferred post-remission therapy for patients with favorable or intermediate risk acute myeloid leukemia? For patients in complete remission without evidence of measurable residual disease, high-dose chemotherapy followed by autologous stem cell transplantation or consolidation chemotherapy are currently considered, where there is a preference for autologous transplantation based on data of the HOVON29 and HOVON42 study.
Dimitris Kotsos presented a poster at the 67th Annual Meeting of the American Society of Hematology entitled "Autologous stem cell transplantation versus consolidation chemotherapy as post-remission treatment in newly diagnosed favorable and intermediate risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials" addressing the question of optimal post-remission treatment in a more recent cohort.
Amica Ko
Amica Ko has also received an ASH Abstract Achievement Award at the 67th Annual Meeting of the American Society of Hematology in December 2025. Her abstract entitled “High risk of bleeding following CAR T-cell therapy: Insights from the Dutch “Follow that CAR!” registry” was awarded with an oral presentation in Orlando.
Although thrombosis and bleeding complications have been increasingly reported following chimeric antigen receptor (CAR) T-cell therapy, their clinical relevance and risk factors remain unclear, also due to heterogeneity between reporting studies.
Amica has investigated the risk of thrombosis and bleeding following CAR T-cell therapy in 250 adult patients with refractory or relapsed (R/R) aggressive large B-cell lymphoma (LBCL), who all received axicabtagene ciloleucel (axi-cel) in the Dutch “Follow that CAR!” multicenter registry. She found that 1-year cumulative incidences of thrombosis and bleeding were 6.3% and 11.0%, respectively. Bleeding was associated with poorer overall survival. Patients who used therapeutic anticoagulation or had thrombocytopenia grade ≥3 (platelet count <50x109/L) at time of CAR T-cell infusion had a significantly higher risk of bleeding. This study confirms the high risk and clinical relevance of particularly bleeding complications after CAR T-cell therapy. Prospective studies are necessary to confirm these results and to guide informed recommendations regarding the use of (therapeutic) anticoagulation or transfusion thresholds in patients receiving CAR T-cell therapy.
Reactie plaatsen
Reacties